Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer

NCT00073398 is registered in ClinicalTrials.gov with NewLink Genetics Corporation as lead sponsor.

NCT NCT00073398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00073398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer
Lead sponsor
NewLink Genetics Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2003
Completion date
March 31, 2013
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of lung, large cell carcinoma, lung neoplasms, non-small cell carcinoma, squamous cell carcinoma